Jabbour SK, Lee KH, Frost N, et al. - Pembrolizumab plus concurrent chemoradiation therapy (cCRT) showed promising antitumor activity as well as manageable safety in patients with previously untreated, locally advanced, stage III non–small cell lung cancer (NSCLC).

• This phase 2, nonrandomized, 2-cohort study (KEYNOTE-799) was conducted to assess treatment outcomes and safety of pembrolizumab plus cCRT in stage III NSCLC.

• Pembrolizumab plus cCRT resulted in objective response rates of 70.5% and 70.6% in cohort A (n = 112; squamous/nonsquamous) and cohort B (n = 102; nonsquamous), respectively.

• In cohorts A and B, incidence of grade 3 or higher pneumonitis was 8.0% and 6.9%, respectively.